Study S001763

A Phase 2, Double-Blind, Proof of Concept Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06817356
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 308
Start: 2025-02-06
Primary completion: 2026-03-19
Lead sponsor: Eli Lilly and Company
Conditions: Alcohol Use Disorder
Interventions: DRUG:Mazdutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8P-MC-OXAH

Registered primary outcomes

Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method [Baseline, Week 28]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.